J&J Adds $6.9bn To Talc Settlement Proposal To Smooth Path To Kenvue Consumer Spinoff
Executive Summary
Firm proposes larger funding agreement to settle North American talc claims, apparently pivoting from appealing to Supreme Court a January circuit court decision upholding bankruptcy court ruling that its LTL subsidiary isn’t “financially distressed” enough to file for Chapter protection.
You may also be interested in...
Consumers Know Kenvue's Brands, But What About ‘Opportunity To Expand Usage Occasions’?
“That’s what makes this space very attractive, the ability to expand usage occasions to give consumers around the world new opportunities to take care of their health,” says CEO Thibaut Mongon. Some investors aren’t clear on what to expect from company operating entirely in consumer health since spinout from J&J.
J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other
Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.
In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’
Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.